Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets
Pierre Stephan,
Jimmy Perrot,
Allison Voisin,
Maud Barbery,
Thibault Andrieu,
Maxime Grimont,
Julie Caramel,
Mathilde Bardou,
Garance Tondeur,
Edoardo Missiaglia,
Philippe Gaulard,
François Lemmonier,
Laurence de Leval,
Emmanuel Bachy,
Pierre Sujobert,
Laurent Genestier,
Alexandra Traverse-Glehen,
Yenkel Grinberg-Bleyer
Affiliations
Pierre Stephan
Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, Lyon
Jimmy Perrot
Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre- Bénite
Allison Voisin
Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, Lyon
Maud Barbery
Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, Lyon
Thibault Andrieu
Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, Lyon
Maxime Grimont
Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, Lyon
Julie Caramel
Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, Lyon
Mathilde Bardou
Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre- Bénite
Garance Tondeur
Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre- Bénite
Edoardo Missiaglia
Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne
Philippe Gaulard
AP-HP, Henri Mondor Hospital, Pathology Department, Créteil, France; University Paris Est Créteil, INSERM, IMRB, Créteil
François Lemmonier
AP-HP, Henri Mondor Hospital, Pathology Department, Créteil, France; University Paris Est Créteil, INSERM, IMRB, Créteil
Laurence de Leval
Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne
Emmanuel Bachy
Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre- Bénite, France; Centre International de Recherche en Infectiologie (CIRI), Team Lymphoma Immuno-Biology, UMR INSERM U1111, CNRS 5308, Université Claude Bernard Lyon I, ENS de Lyon, Lyon
Pierre Sujobert
Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre- Bénite, France; Centre International de Recherche en Infectiologie (CIRI), Team Lymphoma Immuno-Biology, UMR INSERM U1111, CNRS 5308, Université Claude Bernard Lyon I, ENS de Lyon, Lyon
Laurent Genestier
Centre International de Recherche en Infectiologie (CIRI), Team Lymphoma Immuno-Biology, UMR INSERM U1111, CNRS 5308, Université Claude Bernard Lyon I, ENS de Lyon, Lyon
Alexandra Traverse-Glehen
Centre Hospitalier Lyon Sud and Université Claude Bernard Lyon-1, Pierre- Bénite
Yenkel Grinberg-Bleyer
Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Labex DEV2CAN, Centre Léon Bérard, Lyon
Whereas immunotherapies have revolutionized the treatment of different solid and hematological cancers, their efficacy in nodal peripheral T-cell lymphomas (PTCLs) is limited, due to a lack of understanding of the immune response they trigger. To fully characterize the immune tumor microenvironment (TME) of PTCLs, we performed spectral flow cytometry analyses on 11 angioimmunoblastic T-cell lymphomas (AITL), 7 PTCL, not otherwise specified (PTCL, NOS) lymph node samples, and 10 non-tumoral control samples. The PTCL TME contained a larger proportion of regulatory T cells and exhausted CD8+ T cells, with enriched expression of druggable immune checkpoints. Interestingly, CD39 expression was up-regulated at the surface of most immune cells, and a multi-immunofluorescence analyses on a retrospective cohort of 43 AITL patients demonstrated a significant association between high CD39 expression by T cells and poor patient prognosis. Together, our study unravels the complex TME of nodal PTCLs, identifies targetable immune checkpoints, and highlights CD39 as a novel prognostic factor.